Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)Sarah Dyball, Sophie Collinson, Emily Sutton, Eoghan M McCarthy, Ian N Bruce, Ben Parker
23 July 2021
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trialsRaj Tummala, Gabriel Abreu, Lilia Pineda, M Alex Michaels, Rubana N Kalyani, Richard A Furie, Eric F Morand
17 February 2021
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathwaysThomas Dörner, Yoshiya Tanaka, Michelle A Petri, Josef S Smolen, Daniel J Wallace, Ernst R Dow, Richard E Higgs, Guilherme Rocha, Brenda Crowe, Robert J Benschop, Nicole L Byers, Maria E Silk, Stephanie de Bono, Damiano Fantini, Robert W Hoffman
9 October 2020
Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriersCristina Arriens, Teresa Aberle, Fredonna Carthen, Stan Kamp, Aikaterini Thanou, Eliza Chakravarty, Judith A James, Joan T Merrill, Motolani E Ogunsanya
15 March 2020
First use of cenerimod, a selective S1P receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept studyViktoria Hermann, Anastas Batalov, Svetlana Smakotina, Pierre-Eric Juif, Peter Cornelisse
9 November 2019
SLE clinical trials: impact of missing data on estimating treatment effectsMimi Kim, Joan T Merrill, Cuiling Wang, Shankar Viswanathan, Ken Kalunian, Leslie Hanrahan, Peter Izmirly
3 October 2019
Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosusJoan T Merrill, Richard Furie, Victoria P Werth, Munther Khamashta, Jorn Drappa, Liangwei Wang, Gabor Illei, Raj Tummala
26 November 2018
Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC studyRonald F van Vollenhoven, William Stohl, Richard A Furie, Norma Lynn Fox, James G Groark, Damon Bass, Milena Kurtinecz, Bonnie F Pobiner, William J Eastman, Tania Gonzalez‑Rivera, David Gordon
26 November 2018
Evaluating duration of response to treatment in systemic lupus erythematosus clinical trialsMimi Kim, Joan T Merrill, Kenneth Kalunian, Leslie Hanrahan, Peter Izmirly, , for the Lupus Foundation of America Collective Data Analysis Initiative Group, Hahn Hahn, Jan Hillson, Jane Salmon, Nathalie Franchimont, Neil Solomons, Paul Brunetta, Richard Furie, Robert HoffmanSee the full list of authors
6 August 2018
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosusJeffrey M Riggs, Richard N Hanna, Bhargavi Rajan, Kamelia Zerrouki, Jodi L Karnell, Divya Sagar, Inna Vainshtein, Erika Farmer, Kimberly Rosenthal, Chris Morehouse, Melissa de los Reyes, Kevin Schifferli, Meina Liang, Miguel A Sanjuan, Gary P SimsSee the full list of authors
5 April 2018